Please check your internet connection and try again.
# Potassium Chloride
## Overview
Potassium chloride (KCl) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous formulations.
## Primary Indications
* Treatment and prevention of hypokalemia.
## Adult Dosing
* **Oral Replacement:** Doses vary based on serum potassium levels and clinical condition. Typical maintenance: 20 mEq (1.5 g) per day. For more significant deficits: 40-100 mEq (3-7.5 g) per day, divided into 2-5 doses. Maximum oral dose generally not to exceed 100-120 mEq (7.5-9 g) per 24 hours, though higher doses may be used in severe refractory hypokalemia under close monitoring.
* **Intravenous (IV) Replacement:** Doses vary based on serum potassium levels and rate of correction.
* **Mild to Moderate Hypokalemia (serum K 3.0-3.4 mEq/L):** Typically 20-40 mEq (1.5-3 g) added to a large volume IV fluid (e.g., 1 L) administered over 2-6 hours.
* **Severe Hypokalemia (serum K < 2.5 mEq/L) or symptomatic:** May require 10 mEq (0.75 g) every 1-2 hours, often through a central line, with continuous ECG monitoring.
* **Maximum IV Rate:** Generally do not exceed 10-20 mEq/hour (0.75-1.5 g/hour) in peripheral lines to avoid phlebitis and cardiac arrhythmias. Higher rates (up to 40 mEq/hour or 3 g/hour) may be used in critical care settings with central venous access and continuous cardiac monitoring.
* **Maximum IV Concentration:** Generally do not exceed 40 mEq/L (3 g/L) in peripheral IV fluids due to risk of phlebitis. Higher concentrations (up to 80 mEq/L or 6 g/L) may be used in central lines with caution.
## Pediatric Dosing
* Dosing is weight-based and dependent on the severity of hypokalemia. Local institutional protocols are crucial for pediatric IV potassium administration.
* **Oral Replacement:** Typically 1-2 mEq/kg/day, divided into 1-4 doses, not to exceed recommended adult maximums per day.
* **Intravenous (IV) Replacement:**
* **General:** 0.5-1 mEq/kg/dose (0.037-0.075 g/kg/dose) infused over 1-3 hours.
* **Severe Hypokalemia (serum K < 2.5 mEq/L):** May require higher doses, up to 2 mEq/kg/dose (0.15 g/kg/dose) or more, administered more rapidly (e.g., over 1 hour) with continuous ECG monitoring.
* **Maximum IV Rate:** Typically 0.3-0.5 mEq/kg/hour (0.022-0.037 g/kg/hour), but may be increased in severe cases with close monitoring.
* **Maximum IV Concentration:** Typically 40 mEq/L (3 g/L) for peripheral IVs.
## Dose Adjustments
* No dose adjustment needed for renal impairment, but caution is paramount. Patients with renal impairment are at increased risk of hyperkalemia. IV potassium should be used with extreme caution or avoided in severe renal failure. Monitor serum potassium closely.
## Contraindications
* Hyperkalemia.
* Conditions which may predispose to hyperkalemia, such as Addison's disease, untreated Addison's disease, chronic renal insufficiency, rapidly destructive tissue diseases, or certain diuretic therapies (e.g., potassium-sparing diuretics).
* Gastrointestinal obstruction or delayed gastric emptying (for oral extended-release formulations).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence (oral).
* **Serious:** Hyperkalemia (muscle weakness, paralysis, cardiac arrhythmias, cardiac arrest), phlebitis or local tissue necrosis (IV, especially with extravasation or rapid infusion).
## Key Drug Interactions
* **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia.
* **ACE inhibitors and Angiotensin II Receptor Blockers (ARBs):** Can reduce potassium excretion, increasing the risk of hyperkalemia.
* **NSAIDs:** May reduce renal potassium excretion, increasing risk of hyperkalemia.
* **Digoxin:** Hyperkalemia can increase the toxicity of digoxin. Hypokalemia can potentiate digoxin toxicity.
* **Neuromuscular blocking agents:** Hyperkalemia can potentiate the effects of some neuromuscular blocking agents.
## Monitoring
* Serum potassium levels (frequently, especially during IV therapy or dose changes).
* Renal function (BUN, creatinine).
* ECG (especially during rapid IV infusion or in patients with suspected cardiac involvement).
* Signs and symptoms of hypokalemia (weakness, fatigue, constipation, arrhythmias) and hyperkalemia (muscle twitching, weakness, paresthesias, arrhythmias).
## Clinical Pearls
* Oral potassium chloride, especially sustained-release formulations, should be taken with food or meals to minimize gastrointestinal upset.
* Rapid IV infusion or high concentrations can be dangerous and potentially fatal due to the risk of cardiac arrest.
* Always verify IV potassium orders for correct dose, concentration, diluent, and infusion rate. Confirm central line access if higher rates/concentrations are ordered.
* When treating hypokalemia, it is crucial to identify and address the underlying cause.
* Hypomagnesemia often coexists with hypokalemia and may impair potassium repletion; magnesium should be assessed and corrected if deficient.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before administering any medication.*
